Why Moderna Boosters May Not Be Available as Soon as Pfizer-BioNTech Boosters
Coming in No. 2 isn't the ideal outcome for sports teams or companies. Everyone prefers to rank first. However, Moderna (NASDAQ: MRNA) has become accustomed to taking second place.
Moderna lagged behind Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX) in securing Emergency Use Authorization for its COVID-19 vaccine, and its sales have trailed behind its competitors' vaccine, as well. Moderna recently filed for full U.S. Food and Drug Administration (FDA) approval of its vaccine, but Pfizer and BioNTech already won full FDA approval for theirs.
It now looks like Moderna will come in second yet again. Here's why boosters for Moderna's COVID-19 vaccine might not be available as soon as those for Pfizer-BioNTech.
Source Fool.com
